GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GlaxoSmithKline Pharmaceuticals has closed its trading window for insiders from Wednesday, October 1, 2025, until it reopens on Tuesday, November 11, 2025. This closure is in line with SEBI's insider trading regulations and is timed around the company's second-quarter and half-year financial results. The Board of Directors is scheduled to meet on Thursday, November 6, 2025 to approve the unaudited financial results for the period ended September 30, 2025. The window will reopen 48 hours after the results are made public. The communication was signed by Ajay Nadkarni, Vice President – Administration, Real Estate & Company Secretary.
This is a routine compliance disclosure and does not affect shareholders. However, it signals that Q2 FY26 results are due around November 6, 2025, which investors should watch for as it may influence the stock's near-term movement.